睿智醫藥(300149.SZ):公司具備針對糖尿病藥物的包括大分子、小分子藥物發現、藥理藥效、藥代藥動等方面的研發能力
格隆匯5月9日丨睿智醫藥(300149.SZ)在投資者互動平台表示,公司屬於醫藥研發及生產服務(CRO/CDMO)行業,為全球製藥企業、生物技術公司以及科研院校提供藥物發現、開發以及生產服務。 公司具備針對糖尿病藥物的包括大分子、小分子藥物發現、藥理藥效、藥代藥動等方面的研發能力,尤其是擁有相關靶點測試、一型和二型糖尿病的動物模型。公司有為糖尿病藥物研發的客户提供相關研發服務的經驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.